Swiss medical device company SmartCardia SA, a spin-off from research institute and university EPFL, has developed a cordless wearable medical multi-sensor monitoring system that when applied to the patient’s chest can measure a complete set of physiological and vital parameters continuously.
The SmartWearable device, which recently received CE Class IIa certification, accurately measures the Electrocardiogram (ECG), heart rate, heart rate variability, pulse rate, oxygen saturation (SpO2), blood pressure variations and trends, skin temperature, activity and posture.
According to SmartCardia, their wearable device allows for the continuous monitoring and analysis of important vital signs to provide early warning of a health risk.
“Most wearables today measure a limited set of parameters. For clinicians to make informed decisions, several important vitals are needed, and continuously measured in the hospital Intensive Care Units, such as the ECG, SpO2 and blood pressure data,” said CEO and Co-founder of SmartCardia, Dr Srinivasan Murali.
“We have developed a system to measure all the important vitals continuously from a single easy-to-wear unit, and have rigorously validated them in several clinical trials in leading hospitals globally. There is a tremendous response and demand for the system from the different clinics and patients we have been working with,” continued Dr Murali.
SmartCardia’s core technology is based on several years of R&D from top researchers and clinicians across the world. They have collaborated with key opinion leaders across a variety of clinical fields, from cardiovascular surgery, intensive care medicine, anaesthesiology, vascular medicine, sleep and COPD to validate the insights provided by the system.
“We have developed SmartNeuralNet, a world-leading machine learning technology that powers our medical wearables. Our mission is to empower the millions of patients with chronic conditions with actionable insights to improve their health and provide a better quality of life for them and their carers,” said Co-founder and CTO of SmartCardia, Dr Francisco Rincon.
“We have designed the wearable system from ground up to meet the rigorous clinical standards for continuous and efficient patient monitoring,” continued Dr Rincon.
According to the Daily Dot, SmartCardia has already tested the wearable on more than 1,000 patients in 20 clinical trials. Once they conclude their ongoing large-scale trails with more than 2,000 patients they intend to deploy the system in homes.